Graft Versus Host

Graft vs Host Disease After Stem Cell Transplant

Graft vs host disease, usually shortened to GVHD, is an immune complication that can develop after an allogeneic bone marrow or stem cell transplant. It happens when immune cells from the donor — the graft — recognise the recipient’s body — the host — as foreign and begin to attack healthy tissue. Treatment for graft vs host disease aims to calm that attack, protect the affected organs and preserve the benefit of the transplant itself.

For most patients, the transplant marks a turning point after months or years of treatment for leukaemia, lymphoma, myelodysplastic syndromes, aplastic anaemia, an inherited immune deficiency or another serious blood disorder. When GVHD symptoms appear, it is natural to fear that something has gone wrong — that the transplant is failing, that a hospital readmission is coming, that recovery will stall. The reality is more nuanced. GVHD does not mean the transplant has failed. It means the donor immune system is alive and active, and that some of its activity is aimed at the wrong target. The reaction can range from mild and temporary to severe and organ-threatening, and the difference is often decided by how early it is recognised and how carefully it is managed.

Managing graft vs host disease is a balancing act. Suppress the donor immune cells too little and they continue to injure the skin, gut, liver or other organs. Suppress them too much and the patient faces infection risk, drug side effects and, in some blood cancers, a weaker graft-versus-tumour effect — the useful side of donor immunity, in which the same donor cells patrol for residual disease. That balance is why GVHD care belongs in a transplant-experienced centre, where haematologists, transplant physicians, infectious disease specialists, dermatologists, gastroenterologists, pulmonologists, ophthalmologists and nutrition teams can act on the same information at the same time.

For patients and families, the practical concerns are usually continuity and clarity. GVHD treatment may involve frequent blood tests, medication adjustments, imaging, endoscopy or supportive therapies over weeks or months. Understanding what is happening, what the treatment plan involves and how long monitoring may be needed matters as much as the prescriptions themselves.

What is GVHD?

GVHD is a reaction driven mainly by donor T lymphocytes — white blood cells trained to distinguish “self” from “non-self”. In an allogeneic transplant, stem cells come from another person: a matched sibling, an unrelated donor, a partially matched family donor or umbilical cord blood. Even when donor and recipient are well matched on the major tissue markers known as HLA antigens, countless minor differences remain. Donor T cells can read those differences as a threat and mount an inflammatory attack on the recipient’s tissues. Transplant teams anticipate this: nearly every allogeneic transplant includes a GVHD prevention regimen — immunosuppressive drugs given before symptoms ever appear. Prevention reduces the risk; it does not remove it. When symptoms develop despite prophylaxis, the condition becomes GVHD proper and treatment begins.

What does graft versus host disease look like?

The most visible sign of graft versus host disease is a skin rash. In the acute form it often starts as red or darkened patches on the palms, soles, ears, face or shoulders, sometimes itchy or tender, and can spread across the trunk. In severe cases the skin may blister or peel. Beyond the skin, acute GVHD commonly shows itself as watery diarrhoea, cramping abdominal pain, nausea, loss of appetite or jaundice — a yellowing of the skin and eyes from liver involvement. Chronic GVHD looks different: the skin may thicken, tighten or change colour rather than simply redden; the mouth may develop lacy white patches, ulcers or sensitivity to spicy and acidic food; the eyes become persistently dry and gritty; joints stiffen; nails and hair may change. Because the appearance varies so widely between patients and organs, no photograph or description replaces examination by a clinician who has seen the condition many times.

How is GVHD different from host-versus-graft rejection?

The direction of attack is reversed. In a host-versus-graft reaction — the classic “rejection” seen after solid organ transplants — the recipient’s immune system attacks the transplanted tissue. In GVHD, the transplanted immune cells attack the recipient. This is why GVHD is largely a complication of allogeneic stem cell and bone marrow transplantation: the graft in these procedures is not a passive organ but a new, functioning immune system. The distinction matters clinically, because the treatments, monitoring strategies and risks differ between the two situations even though both involve immune conflict between donor and recipient.

Acute and Chronic Graft-versus-Host Disease

Graft-versus-host disease is divided into two broad forms, acute and chronic, and the distinction shapes almost every treatment decision. The two forms differ in timing, in the organs they favour, in how they behave and in how long treatment usually lasts. Some patients experience only one form; others experience acute GVHD early and chronic GVHD later; a smaller group shows overlapping features of both at once.

Acute GVHD

Acute GVHD usually appears in the early months after transplant, although it can occur later, particularly after reduced-intensity conditioning or donor lymphocyte infusions. It most often affects three organ systems: the skin, the gastrointestinal tract and the liver. Symptoms may include rash, diarrhoea, abdominal pain, nausea, vomiting, elevated liver enzymes or jaundice. Clinicians stage each involved organ and combine the stages into an overall grade, from mild disease limited to a small area of skin through to severe multi-organ involvement. The grade guides how aggressive treatment needs to be and how closely the patient must be watched.

Chronic GVHD

Chronic GVHD may develop months after transplant and behaves less like an acute inflammation and more like an autoimmune or fibrosing disease. It can affect the skin, mouth, eyes, lungs, joints, muscles, fascia, liver, gastrointestinal tract, genital tissues and other organs — sometimes one at a time, sometimes several together. Typical problems include dry eyes, mouth sores, skin tightening, shortness of breath, fatigue, joint stiffness, difficulty swallowing and recurrent infections. Chronic GVHD is classified by severity — mild, moderate or severe — based on how many organs are involved and how much each is affected. Because it can smoulder for a long time, the treatment goal shifts from rapid control towards preserving function, preventing scarring and protecting quality of life over months and years.

Who Develops GVHD, and When

Anyone who has received an allogeneic stem cell or bone marrow transplant can develop GVHD, but the risk is not uniform. It depends on how closely the donor and recipient are matched, the stem cell source, the intensity of the conditioning regimen, the GVHD prevention strategy used, the patient’s age, the underlying disease and its status at transplant, prior infections — particularly cytomegalovirus exposure — and other individual factors. A well-matched sibling donor generally carries a different risk profile from a partially matched or unrelated donor, and cord blood transplants behave differently again. None of these factors predicts the outcome for an individual patient with certainty; they shape probability, not destiny.

Timing offers clues but not answers. Symptoms in the first weeks and months after transplant more often reflect acute GVHD; symptoms appearing later, or evolving slowly, more often reflect the chronic form. Certain changes after transplant are more typical of GVHD than of routine recovery: new skin changes, persistent diarrhoea, abdominal pain, nausea or vomiting, yellowing of the skin or eyes, dark urine, unexplained fever, mouth ulcers, marked dryness of the eyes or mouth, breathing changes and rapidly worsening fatigue. Symptoms can be subtle at first, and early recognition helps clinicians distinguish GVHD from infection, medication toxicity, relapse of the underlying disease, nutritional problems or other transplant-related complications — several of which can coexist in the same patient at the same time.

Not every patient with GVHD needs the same intensity of care. Some develop mild disease requiring topical treatment and careful monitoring. Others have moderate disease requiring systemic immunosuppression as outpatients. Severe cases may require hospitalisation, intravenous medications, fluid replacement, nutritional support and intensive infection surveillance. Chronic GVHD may need long-term multidisciplinary care, because its symptoms touch daily comfort, mobility, nutrition, vision, breathing and independence.

Organs and Problems GVHD Treatment Addresses

GVHD treatment targets both the underlying immune process and the organ-specific damage it causes. The indication for treatment depends on the pattern and severity of involvement.

• Skin GVHD: rash, itching, redness, peeling, thickening, pigment changes or skin tightening that affects comfort, movement and infection risk.
• Gastrointestinal GVHD: diarrhoea, abdominal cramping, nausea, vomiting, poor appetite, weight loss, bleeding or protein loss that can lead to dehydration and malnutrition. Some chronic gut symptoms can superficially resemble inflammatory bowel conditions such as Crohn disease or the malabsorption seen in celiac disease, which is one reason biopsy confirmation matters.
• Liver GVHD: elevated liver enzymes, impaired bile flow, jaundice, dark urine or abdominal discomfort — findings that must be carefully separated from medication toxicity, infection, relapse and other forms of liver disease.
• Oral and eye involvement: mouth ulcers, sensitivity to spicy or acidic foods, dry mouth, dental complications, dry eyes, irritation, light sensitivity and other vision-related symptoms.
• Lung involvement: chronic inflammation or narrowing of the small airways, which may cause cough, wheezing, shortness of breath or reduced exercise tolerance — changes that pulmonary function testing can detect before the patient feels them.
• Musculoskeletal and connective tissue involvement: joint stiffness, muscle weakness, cramps, tightening of skin or fascia and reduced range of motion.
• Genital and urinary symptoms: dryness, discomfort, inflammation, scarring or pain that deserve sensitive, specialist evaluation rather than silence.
• Systemic immune complications: increased infection risk, fatigue, delayed immune recovery and the need for structured revaccination planning after transplant.

The purpose of treatment is to control inflammation before it causes lasting organ damage. For chronic GVHD, treatment also focuses on preserving function, preventing disability and helping patients return safely to their daily routines.

How GVHD Is Diagnosed

Diagnosis begins with a detailed clinical evaluation rather than a single test. The haematology and transplant team reviews the transplant history, donor type and match, conditioning regimen, GVHD prophylaxis used, current medications, the timing of symptoms and any previous complications. Blood tests assess liver and kidney function, blood counts, inflammation, immune recovery and — where relevant — the levels of immunosuppressive drugs, some of which need precise dosing to work safely. When diarrhoea is present, stool studies help rule out infection. Viral monitoring, particularly for cytomegalovirus in susceptible patients, is important because viral reactivation can both mimic and worsen GVHD; this surveillance is usually coordinated with infectious diseases specialists.

When organ involvement needs confirmation, specialists take tissue or perform targeted testing. Dermatologists can biopsy the skin. Gastroenterologists can perform endoscopy with small biopsies of the gut lining. Hepatologists evaluate the liver. Pulmonologists measure lung function and review chest imaging. Ophthalmologists examine the surface of the eye. Pathology review helps confirm that the tissue changes are consistent with GVHD rather than infection or drug injury — though when symptoms are significant, treatment may begin before every result is back, because waiting has its own cost.

Which ICD-10 code covers graft-versus-host disease?

Graft-versus-host disease is coded under D89.81 in the ICD-10 classification, with more specific codes for its forms: D89.810 for acute GVHD, D89.811 for chronic GVHD, D89.812 for acute-on-chronic disease and D89.813 when the form is unspecified. Patients rarely need these codes day to day, but they appear on medical reports, insurance paperwork and referral letters, so recognising them helps when reading your own records or transferring care between hospitals.

How GVHD Treatment Works: From Evaluation to Recovery

GVHD care follows a structured sequence: confirm what is happening, treat at the right intensity, monitor the response and adjust. Because GVHD, infection and drug toxicity can overlap, the first step is usually a careful diagnostic pathway rather than an automatic escalation of immune suppression in every patient.

How is GVHD prevented in the first place?

GVHD prevention starts before symptoms ever appear: nearly every allogeneic transplant includes a prophylaxis regimen given around the time of the transplant itself. Common approaches combine a calcineurin inhibitor such as cyclosporine or tacrolimus with methotrexate or mycophenolate; some protocols use post-transplant cyclophosphamide, anti-thymocyte globulin or techniques that reduce the number of T cells in the graft. The choice depends on the donor type, the stem cell source, the conditioning intensity and the underlying disease. It also shapes how later GVHD — if it occurs — is treated, because the drugs already on board influence what can safely be added, and because a breakthrough despite strong prophylaxis tells the team something about how the disease is likely to behave.

Initial evaluation and preparation

The physician reviews the transplant timeline, donor source, conditioning therapy, the prophylaxis regimen and every current medication. Blood tests evaluate complete blood counts, organ function, inflammation markers and immunosuppressive drug levels where relevant. Microbiology testing looks for bacterial, viral, fungal or parasitic infections; stool testing is essential when diarrhoea is present, and imaging plus pulmonary function testing when breathing is affected. Preparation also includes a medication review, because some drugs interact with immunosuppressants or add to infection risk. Depending on the plan, the team may adjust antimicrobial prophylaxis, stomach protection, blood pressure control, diabetes management, bone protection or nutritional support — always as part of a coordinated prescription, decided by the treating physicians.

The treatment plan

Treatment intensity follows disease severity, broadly in this order:

1. Mild disease: topical corticosteroids, medicated creams, oral rinses, eye drops, moisturisers, sun protection, dietary adjustment and close follow-up. Local therapy can control limited disease without exposing the whole body to immunosuppression.
2. Moderate to severe disease: systemic immunosuppression, most commonly corticosteroids as first-line therapy, often alongside continuation or adjustment of transplant medications such as calcineurin inhibitors. Dose and duration depend on severity and response. Steroids carry their own burden — raised blood sugar, mood changes, muscle weakness, bone loss, infection risk — so the team monitors closely and reduces the dose when it is medically safe to do so.
3. Steroid-refractory or recurrent disease: if GVHD does not respond adequately, or returns during tapering, additional options are considered — targeted immune-modulating drugs, biologic therapies, extracorporeal photopheresis or other specialist-directed treatments. The choice depends on the organs involved, infection risk, prior therapies, blood counts, liver and kidney function and the patient’s overall condition.

Extracorporeal photopheresis, used in selected cases — particularly some forms of chronic or steroid-refractory GVHD — is a procedure in which blood cells are collected through a vein, treated outside the body with a light-activated medication and ultraviolet light, then returned to the patient. Sessions usually take several hours and follow a schedule set by the transplant team. It is one of several tools, not a universal answer, and its role is decided case by case.

Crucially, GVHD treatment is not one prescription but a process of continuous reassessment. At each review the team asks the same questions: are symptoms improving, are drug side effects emerging, is an infection present, and is the underlying blood disease still controlled? The plan may change over days, weeks or months as the new immune system matures.

Supportive care alongside immunosuppression

Supportive care carries as much weight in GVHD as the immunosuppressive drugs themselves, because it protects the body while the immune reaction is brought under control. For the skin, that means regular emollients, gentle cleansing and strict sun protection, since ultraviolet light can aggravate skin GVHD. For the mouth, medicated rinses, careful oral hygiene and dental review reduce pain and infection risk. Persistently dry eyes are managed stepwise — lubricating drops and gels first, then measures such as punctal plugs or specialised lenses when dryness threatens the eye surface. When the gut is involved, dietitians adapt the diet to what the intestine can absorb, and temporarily feeding by vein may be needed when it cannot. Physiotherapy and structured stretching preserve movement when skin or fascia tighten, bone-protective measures accompany long steroid courses, antimicrobial prophylaxis guards against opportunistic infection, and psychological support is offered deliberately, because months of treatment after a transplant test even the most resilient patients and families.

Technology used in GVHD care

Modern GVHD management leans on diagnostic and monitoring technology to keep decisions precise. Laboratory platforms track blood counts, organ function, immune recovery, drug levels and viral reactivation. Molecular tests monitor chimerism — the proportion of blood cells derived from the donor — and infectious risk. Pathology review of biopsy samples separates GVHD from infection, drug injury and other inflammatory conditions. Endoscopy lets physicians inspect the gut and sample tissue when diarrhoea or bleeding needs explanation. Pulmonary function testing catches early airflow changes; ophthalmic tools assess the eye surface and guide treatment for chronic dryness. The value of all this lies in integration: in GVHD, a single test rarely gives the whole answer. The best decisions combine examination findings, laboratory trends, tissue results, imaging and the patient’s own account of daily symptoms.

Follow-up and the recovery process

Follow-up is frequent at first — regular blood tests, infection surveillance, drug-level checks and structured symptom scoring — and the interval stretches as things stabilise. Recovery itself is rarely linear. Some symptoms improve quickly; others, such as dry eyes, skin changes, fatigue or reduced lung capacity, need longer rehabilitation and supportive care. Many patients benefit from nutritional counselling, infection-prevention education, physiotherapy, dental care, ongoing eye treatment and a revaccination plan as the immune system rebuilds. The team also watches for treatment side effects: bone health, muscle strength, blood sugar, blood pressure and mental wellbeing all deserve attention during prolonged steroid therapy. When care is shared between a transplant centre and a local haematology team, medication changes and monitoring results are coordinated between them so that adjustments happen without delay.

Why Acting Early Matters

GVHD can move quickly. A mild rash may spread; diarrhoea may tip into dehydration; liver inflammation may deepen; a slight cough may signal early airway involvement. Early treatment reduces the risk of severe organ injury and often lets physicians use more measured therapy before complications become entrenched. Delay also muddies the diagnosis: infections, drug reactions and GVHD overlap after transplant, and every day of untreated symptoms makes them harder to separate. Patients who go days without evaluation may become weaker, lose weight, develop electrolyte disturbances or need admission. Severe gastrointestinal GVHD can impair absorption of the very oral medications meant to treat it. Chronic GVHD, when recognised late, can leave scarring, stiffness, eye damage or reduced lung capacity that is harder to reverse than to prevent. This is why transplant follow-up is structured the way it is: early assessment lets the team decide whether a change can simply be watched, managed with local measures or needs closer evaluation — a decision far easier to make well when the change is days old rather than weeks.

Benefits of Graft-versus-Host Disease Treatment

The benefits of treatment depend on the severity and organs involved, but the goals are consistent: control immune injury, protect organ function and support a safe transplant recovery.

Benefit	What It Means for You
Control of harmful immune activity	Treatment reduces the donor immune-cell attack on the skin, gut, liver, lungs, eyes and other organs.
Protection of organ function	Early, appropriate therapy lowers the risk of dehydration, malnutrition, liver dysfunction, lung decline and tissue scarring.
Improved daily comfort	Managing rash, itching, diarrhoea, mouth pain, dry eyes and stiffness helps you eat, sleep, move and function.
Safer immune suppression	Close monitoring balances GVHD control against infection prevention and medication side effects.
Coordinated long-term recovery	Specialist follow-up supports rehabilitation, nutrition, vaccination planning and the return to daily life after transplant.

Recovery Timeline After GVHD Treatment

Recovery varies widely between patients, but the following timeline gives a realistic sense of the phases many people move through once treatment begins.

Time Period	What Patients Can Expect
Day 1	Evaluation of symptom severity, organ involvement, infection testing and medication review. Treatment may begin immediately if GVHD is likely or severe.
First week	Frequent blood tests, symptom checks and adjustments to immunosuppressive therapy. Hydration, nutrition and infection prevention are closely managed.
First month	Improvement often becomes clearer, especially in skin and gastrointestinal symptoms. Medication tapering is considered only when medically safe.
Several months	Some patients continue systemic therapy, supportive treatments and organ-specific care. Chronic symptoms may need rehabilitation and specialist follow-up.
Longer term	Focus shifts to maintaining remission, preventing infection, managing late effects and coordinating care with the home medical team.

How long does graft-versus-host disease last?

It depends on the form. Mild acute GVHD may settle over days to weeks with appropriate treatment, while more significant acute disease can need weeks or months of systemic therapy followed by a careful taper. Chronic GVHD lasts longer by nature: treatment often continues for many months, sometimes longer, particularly when several organs are involved. Some patients reach a point where medication is withdrawn entirely; others need low-level therapy or organ-specific care — eye drops, skin care, physiotherapy — for an extended period. The honest answer is that no clinician can promise a fixed end date at the start; the timeline reveals itself through response to treatment.

How long does it take to recover from GVHD?

Recovery from GVHD usually takes longer than the resolution of its most visible symptoms. A rash may fade within weeks while fatigue, dry eyes, reduced stamina or stiffness improve over months of rehabilitation and supportive care. Recovery also includes coming off immunosuppression safely, rebuilding strength and nutrition, completing infection precautions and, eventually, revaccination as immune function returns. Patients recovering from severe or multi-organ disease should expect a gradual, staged process rather than a single moment of being better — and should measure progress in monthly trends, not daily fluctuations.

Outlook: Living With and Beyond GVHD

Questions about outlook are the ones patients most want answered and the ones least suited to simple numbers. Published outcomes vary enormously with the form of disease, its grade, the organs involved, the response to first-line treatment and the health of the patient going in — which is why a single quoted survival figure would mislead more than it would inform. What can be said honestly is set out below.

Can graft vs host be cured?

Clinicians are careful with the word cure here, and you should be wary of anyone who is not. Acute GVHD can resolve completely with treatment, and many patients eventually stop immunosuppressive therapy altogether. Chronic GVHD more often follows a relapsing-and-settling course: it can enter long, stable remission, but some patients retain residual changes — dryness, skin alteration, reduced lung reserve — even after the active disease quietens. The realistic goal of treatment is durable control with the least possible medication, protection of organ function and a return to normal life, rather than a promised cure.

Can you die from graft versus host disease?

Yes — severe GVHD is a serious condition, and it can be fatal, most often through severe gut or liver involvement, progressive lung disease or the infections that accompany heavy immunosuppression. That is precisely why transplant teams monitor so intensively, treat early and escalate quickly when first-line therapy does not work. It is equally true that the majority of GVHD is not the catastrophic form: much of it is mild or moderate, responds to treatment and settles. The severity at diagnosis and the response to initial therapy tell a doctor far more about an individual’s risk than any general statement can.

Can you live with graft vs host disease?

Yes. Many people live full, active lives during and after treatment for chronic GVHD, working, travelling and raising families while managing residual symptoms the way others manage any long-term condition. Living well with GVHD usually means a routine: taking medication exactly as prescribed, attending monitoring visits, protecting the skin from sun, keeping eyes and mouth moist, staying vigilant about infection, maintaining nutrition and exercise within tolerance, and keeping an open line to the transplant team so that changes are assessed early rather than late. Quality of life is a legitimate treatment goal in its own right, not an afterthought.

Factors That Influence Outcomes

Outcomes in GVHD are shaped by several clinical factors, which is why treatment must be personalised rather than protocol-only. The most important is severity at diagnosis: mild disease limited to the skin behaves very differently from severe gastrointestinal or lung involvement. The number of organs affected, the speed of progression and the response to first-line therapy carry similar weight. Timing matters too — disease recognised early can be treated before dehydration, infection, malnutrition or organ damage develops, whereas advanced disease demands more intensive treatment and is harder to control.

The patient’s immune status is another key variable. After transplant the immune system is still under construction; patients with low blood counts, recent infections, viral reactivation or significant organ dysfunction may need a more cautious strategy. Drug tolerance and interactions influence the choice of agents — some immunosuppressants require ongoing kidney, liver or blood-pressure monitoring. The transplant itself leaves fingerprints on the risk profile: donor match, stem cell source, conditioning intensity, the prophylaxis regimen used and the status of the underlying disease all affect how GVHD behaves. A patient transplanted for acute leukaemia may weigh priorities differently from one transplanted for aplastic anaemia or an inherited immune disorder, because the value of preserving donor immune activity against residual disease differs between them.

Good outcomes are supported by unglamorous consistency: accurate medication use, kept appointments, infection precautions, nutritional support and prompt communication between patient and team, so that nothing important is left to guesswork. For chronic GVHD, success is also measured in function: better eye comfort, less mouth pain, more flexible skin, improved stamina, stable lung tests and a falling steroid dose. Those goals take patience, but they are the substance of life after transplant.

GVHD Care at Acibadem

GVHD care needs an environment where complex immune complications can be assessed quickly and managed across specialties under one roof. At Acibadem, patients with GVHD are managed within hospitals that bring together haematology and transplant medicine, infectious disease expertise, intensive care when needed, diagnostic imaging, pathology, laboratory monitoring and the organ-specific services — dermatology, gastroenterology, pulmonology, ophthalmology — that this condition so often requires simultaneously. When appropriate, cases are discussed through multidisciplinary boards, because a decision that helps one organ can carry consequences for another, and those trade-offs are best weighed collectively.

Care planning is individual. The haematology team works from the patient’s transplant background, current symptoms, prior treatments, infection history and goals, and diagnostic pathways support each step: laboratory monitoring of blood counts, organ function, immune status, drug levels and infectious complications; imaging, endoscopy, biopsy interpretation, pulmonary function testing and ophthalmic evaluation when clinically indicated. These tools help physicians distinguish GVHD from its convincing imitators — viral infection, drug toxicity, relapse of the underlying disease. Technology guides decisions; it does not replace judgement. A rash, an abnormal liver test or an episode of diarrhoea only means something in the full transplant context, read by physicians who have seen the pattern before.

Coordination is part of safety in this condition. Patients with GVHD typically arrive with long transplant histories and extensive medication lists, so an organised review of prior records precedes any decision. How long care takes depends on the situation: some patients come for a second opinion, medication optimisation or evaluation of chronic symptoms, while acute or severe disease may need inpatient care and a longer monitoring window before the intensity of follow-up can ease. Where ongoing care continues with a local haematology team, coordination between physicians keeps medication changes and monitoring results managed without delay. Communication runs through all of it: GVHD treatment shifts as the patient responds, and families do better when they understand why a biopsy is needed, why steroids taper slowly, why infection testing repeats and why some symptoms take time. Clear explanation is not a courtesy in this disease — it is part of the treatment.

Graft-versus-host disease is a demanding complication arriving at a vulnerable moment, after the physical and emotional effort of transplant itself. But it is a treatable one. With timely diagnosis, carefully balanced immune management and consistent follow-up, most patients can be helped through it — and the plan that helps them is always the one built around their particular disease, their particular organs and their particular transplant course.